Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI -1.26%72 ROC (Joel Greenblatt) % is 189.87% as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.80 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Sanara MedTech ranks better than 95.94% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sanara MedTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 189.87%.
The historical rank and industry rank for Sanara MedTech's ROC (Joel Greenblatt) % or its related term are showing as below:
SMTI'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -652.33 Med: -174.07 Max: 220.77
Current: 88.8
During the past 13 years, Sanara MedTech's highest ROC (Joel Greenblatt) % was 220.77%. The lowest was -652.33%. And the median was -174.07%.
SMTI's ROC (Joel Greenblatt) % is ranked better than 95.94% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs SMTI: 88.80
Sanara MedTech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sanara MedTech ROC (Joel Greenblatt) % Related Terms
Sanara MedTech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs EMBC, KRMD, UTMD: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 189.87% mean?
Sanara MedTech (SMTI) has a ROC (Joel Greenblatt) % of 189.87% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #34 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 4.1%.
Is Sanara MedTech's ROC (Joel Greenblatt) % too high?
Sanara MedTech's current ROC (Joel Greenblatt) % is 189.87%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Sanara MedTech's value of 189.87% is 4480.7% above this industry median. Based on the distribution chart, Sanara MedTech ranks #34 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's ROC (Joel Greenblatt) % compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #34 out of 838 companies for ROC (Joel Greenblatt) %. This places Sanara MedTech in the top 4% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Sanara MedTech's value of 189.87% is 4480.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current ROC (Joel Greenblatt) % of 189.87% is 4480.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current ROC (Joel Greenblatt) % is 189.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.80, compared to a current price of $25.00 — trading 45.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 189.87% and 4480.7% above the Medical Devices & Instruments industry median of 4.15. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current ROC (Joel Greenblatt) % is 189.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $25.00 is trading 45.4% below its estimated GF Value™ of $45.80.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
ROC (Joel Greenblatt) %: 189.87%
GF Value™: $45.80 vs. price of $25.00 (45.4% below fair value)
Industry Position: 4480.7% above the Medical Devices & Instruments median (#34 of 838)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
